Showing 19,961 - 19,980 results of 21,342 for search '(( significant ((fold decrease) OR (a decrease)) ) OR ( significant decrease decrease ))', query time: 0.69s Refine Results
  1. 19961

    Table 1_Modified maxillomandibular advancement for Eastern Asian patients with moderate or severe OSA: an anatomic and aerodynamic assessment of the upper airway.xlsx by Kan Li (490394)

    Published 2025
    “…The apnea–hypopnea index (36.05 ± 17.68 vs. 5.72 ± 4.76, p < 0.001) and the ESS (13.23 ± 8.9 vs. 6.23 ± 6.81 events/h, p < 0.05) decreased significantly, while the lowest oxygen saturation (76.54 ± 10.26% vs. 84.77 ± 6.02%, p < 0.05) improved greatly. …”
  2. 19962

    Table_3_Association of glymphatic system dysfunction with cognitive impairment in temporal lobe epilepsy.docx by Jiajia Wang (157207)

    Published 2024
    “…Correlation analyses found that SVF performance was significantly or borderline significantly associated with glymphatic function (FDR-corrected p < 0.05 for all DTI-ALPS index and FDR-corrected p = 0.057 for CPV) in TLE patients. …”
  3. 19963

    Table_1_Association of glymphatic system dysfunction with cognitive impairment in temporal lobe epilepsy.docx by Jiajia Wang (157207)

    Published 2024
    “…Correlation analyses found that SVF performance was significantly or borderline significantly associated with glymphatic function (FDR-corrected p < 0.05 for all DTI-ALPS index and FDR-corrected p = 0.057 for CPV) in TLE patients. …”
  4. 19964

    Data_Sheet_1_Association of glymphatic system dysfunction with cognitive impairment in temporal lobe epilepsy.docx by Jiajia Wang (157207)

    Published 2024
    “…Correlation analyses found that SVF performance was significantly or borderline significantly associated with glymphatic function (FDR-corrected p < 0.05 for all DTI-ALPS index and FDR-corrected p = 0.057 for CPV) in TLE patients. …”
  5. 19965

    Baseline characteristics of participants. by Mei Zhou (269746)

    Published 2025
    “…</p><p>Results</p><p>After DRG implementation, the logarithmic mean of total hospitalization expenditures decreased significantly (3.914 ± 0.837 vs. 3.872 ± 1.004), while rates of unplanned readmissions, unplanned reoperations, postoperative complications, and patient complaints within 30 days increased significantly (3.784% vs 4.214%, 0.083% vs 0.166%, 0.207% vs 0.258%, 3.741% vs 5.133%). …”
  6. 19966

    The framework diagram of this study. by Mei Zhou (269746)

    Published 2025
    “…</p><p>Results</p><p>After DRG implementation, the logarithmic mean of total hospitalization expenditures decreased significantly (3.914 ± 0.837 vs. 3.872 ± 1.004), while rates of unplanned readmissions, unplanned reoperations, postoperative complications, and patient complaints within 30 days increased significantly (3.784% vs 4.214%, 0.083% vs 0.166%, 0.207% vs 0.258%, 3.741% vs 5.133%). …”
  7. 19967

    Table 1_Exploring the alleviating effects of Bifidobacterium metabolite lactic acid on non-alcoholic steatohepatitis through the gut-liver axis.docx by Hongmei Zhao (250090)

    Published 2025
    “…</p>Results<p>In vivo findings indicated that, in comparison to CBX group (Control group without antibiotic treatment), NAFLD/CBX group (NAFLD group without antibiotic administration) and NAFLD/ABX group (NAFLD group with antibiotic administration) exhibited increased liver-to-body weight ratio, higher lipid droplet accumulation, aggravated liver histopathological damage, and elevated levels of AST (Aspartate Aminotransferase), ALT (Alanine Aminotransferase), TC (Total Cholesterol), TG (Triglycerides), LDL-C (Low-Density Lipoprotein Cholesterol), IL-6 (Interleukin-6), TNF-α (Tumor Necrosis Factor-alpha), IL-1β (Interleukin-1 beta), and NLRP3-related molecules, while HDL-C (High-Density Lipoprotein Cholesterol) levels significantly decreased. Intervention with Bifidobacterium significantly reversed these adverse changes. …”
  8. 19968

    Data Sheet 1_Lysate of Parabacteroides distasonis prevents severe forms of experimental autoimmune encephalomyelitis by modulating the priming of T cell response.docx by Zuzana Jiraskova Zakostelska (6386825)

    Published 2024
    “…EAE induction was the main factor in altering the gut microbiota, decreasing the abundance of lactobacilli and segmented filamentous bacteria. …”
  9. 19969

    Data Sheet 1_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  10. 19970

    Data Sheet 3_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  11. 19971

    Table 1_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.xls by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  12. 19972

    Image 1_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.jpeg by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  13. 19973

    Data Sheet 5_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  14. 19974

    Data Sheet 2_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  15. 19975

    Data Sheet 8_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  16. 19976

    Data Sheet 6_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  17. 19977

    Data Sheet 7_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  18. 19978

    Data Sheet 4_The role and impact of the IL-6 mediated JAK2-STAT1/3 signaling pathway in the pathogenesis of gout.zip by Zeng Zhang (299463)

    Published 2025
    “…Background<p>Interleukin-6 (IL-6) is a pleiotropic cytokine, with specific effects depending on the immune microenvironment. …”
  19. 19979

    Quantitative real-time PCR primer sequences. by Lydie M. O. Barbeau (5941712)

    Published 2025
    “…<div><p>In the last decade, advancements in understanding the genetic landscape of lung squamous cell carcinoma (LUSC) have significantly impacted therapy development. Immune checkpoint inhibitors (ICI) have shown great promise, improving overall and progression-free survival in approximately 25% of the patients. …”
  20. 19980

    MAP1LC3C shRNA sequences. by Lydie M. O. Barbeau (5941712)

    Published 2025
    “…<div><p>In the last decade, advancements in understanding the genetic landscape of lung squamous cell carcinoma (LUSC) have significantly impacted therapy development. Immune checkpoint inhibitors (ICI) have shown great promise, improving overall and progression-free survival in approximately 25% of the patients. …”